Approximately 70% of breast cancer cases are classified as hormone receptor-positive (HR+) malignancies, wherein tumor growth, survival, and progression are mechanistically driven by estrogen receptor (ER) expression and activation (Ríos-Hoyo et al., 2024). Here, NR4A1 is linked to neoplasm.